Safety of long‐term treatment with risankizumab in patients with moderate‐to‐severe plaque psoriasis

Abstract

British Journal of DermatologyVolume 186, Issue 3 p. e119-e119 Plain Language SummaryFree Access Safety of long-term treatment with risankizumab in patients with moderate-to-severe plaque psoriasis First published: 07 March 2022 https://doi.org/10.1111/bjd.20992AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Linked Article: Gordon et al. Br J Dermatol 2022; 186:466–475. Psoriasis is a common, chronic, inflammatory skin disease that produces red, scaly patches. It negatively affects patients’ quality of life and is associated with several other diseases, including cardiovascular disease, hypertension, hyperlipidaemia, diabetes and depression. Approximately 100 million people worldwide have psoriasis. Risankizumab is approved for the treatment of moderate-to-severe plaque psoriasis in more than 70 countries. In this study, with authors from around the world, we looked at the long-term safety of risankizumab using data from 17 different clinical trials of risankizumab. These studies had been conducted in a number of countries. We gathered together all the data from these different studies and in total they included information about more than 3000 patients. Added together this way we were able to look at over 7900 patient-years of exposure to risankizumab. We looked at whether this treatment resulted in an increase in adverse events such as respiratory infections, injection-site reactions and cancers. The results were reassuring. These findings about its safety support risankizumab as a long-term treatment option for patients with moderate-to-severe psoriasis. Volume186, Issue3March 2022Pages e119-e119 RelatedInformation